Pfizer's CEO Albert Bourla said that he's had dinner with Trump's health secretary pick, RFK Jr.Bourla said he was ...

CEO Bourla sees "a lot of opportunities that probably outweigh the risks" with the Trump administration, like working together on cancer treatments ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...

Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.

Pfizer Chairman and CEO Albert Bourla did not mince his words at the 43rd annual J.P. Morgan Healthcare Conference in San Francisco on Monday regarding the controversial positions that Robert F.

SAN JOSE, Calif.--(BUSINESS WIRE)--Takara Bio USA Holdings, Inc. (“TBUSH”) today announced the acquisition of Curio Bioscience, a pioneering company in the field of spatial genomics.

Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu is the next pandemic, and more. Bollywood star Priyanka Chopra ...

Other previous laureates have included Michael Bloomberg, Itzhak Perlman, Ruth Bader Ginsburg, and Albert Bourla. The foundation has given more than $50 m. to philanthropic causes around the world ...

Its high debt load remained a cause of investor concern for the entire year, and as a result, CEO Albert Bourla’s turnaround strategy is now a key part of Pfizer Inc. (NYSE:PFE)’s hypothesis.

When asked about the visibility into the business, Albert Bourla added that the main difference between 2024 and 2025 is the stabilization of the COVID business. In 2024, guidance reflected ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” ...